Warning letter
This article was originally published in The Tan Sheet
Executive Summary
Online retailer of Immune-Assist 247 supplement Anthony Peters receives an FDA warning letter for labeling that contains "serious violations" of the FDC Act. Claims on the website tout the product as an "adjunct therapy in HIV" treatment and report "amazingly positive" results for the product in human trials for HIV and hepatitis C. These claims and others classify Immune-Assist 247 as a drug under the FDC Act because the product is intended to diagnose, cure, mitigate, treat or prevent a human disease, FDA maintains. Additionally, the firm also is in violation of the FDC Act for marketing an unapproved new drug since a New Drug Application (NDA) has never been submitted for the product. FDA requests a response from Peters within 15 business days outlining the steps he is taking to rectify the violations...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.